Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Study Summary

NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.

Conditions

Advanced Solid Tumor HER2-negative Breast Cancer Metastatic Castration-resistant Prostate Cancer (mCRPC)Pancreatic Cancer Platinum-resistant Ovarian Cancer (PROC)

Interventions / Drugs

NUV-1511

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment466 participants

Primary Completion—

Lead SponsorNuvation Bio Inc.

Data Retrieved2026-04-11 04:23:06.088444+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.